AR026832A1 - Dispositivo que contiene alprazolam y un agente antipsicotico. - Google Patents
Dispositivo que contiene alprazolam y un agente antipsicotico.Info
- Publication number
- AR026832A1 AR026832A1 ARP010100117A ARP010100117A AR026832A1 AR 026832 A1 AR026832 A1 AR 026832A1 AR P010100117 A ARP010100117 A AR P010100117A AR P010100117 A ARP010100117 A AR P010100117A AR 026832 A1 AR026832 A1 AR 026832A1
- Authority
- AR
- Argentina
- Prior art keywords
- external cover
- osmotic
- antipsychotic agent
- device containing
- spraying
- Prior art date
Links
- 239000000164 antipsychotic agent Substances 0.000 title abstract 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 title 1
- 229960004538 alprazolam Drugs 0.000 title 1
- 230000003204 osmotic effect Effects 0.000 abstract 3
- 238000005507 spraying Methods 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Provee un dispositivo osmotico que contiene alprazolan de liberacion controlada en el nucleo, opcionalmente en combinacion con un agente antipsicotico enuna cubierta externa de liberacion rápida. Un amplio rango de agentes antipsicoticos pueden ser u tilizados en este dispositivo. Realizaciones particulares dela invencion proveen dispositivos osmoticos con perfiles de liberacion predeterminados. Una realizacion preferida del dispositivo osmotico incluye una cubiertaexterna que ha sido aplicada po r pulverizacion en vez de ser aplicada por compresion en el dispositivo. El dispositivo con la cubierta externa aplicada porpulverizacion es más pequeno y fácil de tragar que un dispositivo similar con una cubierta externa aplicada por compresion. El dispositivo es util para eltratamiento de los desordenes relacionados con la depresion, la ansiedad o la psicosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17582700P | 2000-01-13 | 2000-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026832A1 true AR026832A1 (es) | 2003-02-26 |
Family
ID=22641798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100117A AR026832A1 (es) | 2000-01-13 | 2001-01-11 | Dispositivo que contiene alprazolam y un agente antipsicotico. |
Country Status (6)
Country | Link |
---|---|
US (1) | US6599532B2 (es) |
AR (1) | AR026832A1 (es) |
AU (1) | AU2001227758A1 (es) |
CA (1) | CA2396214A1 (es) |
UY (1) | UY26534A1 (es) |
WO (1) | WO2001051040A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040213848A1 (en) * | 2001-09-28 | 2004-10-28 | Shun-Por Li | Modified release dosage forms |
US20040146559A1 (en) * | 2002-09-28 | 2004-07-29 | Sowden Harry S. | Dosage forms having an inner core and outer shell with different shapes |
US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
PT1539115E (pt) * | 2002-07-29 | 2008-01-14 | Alza Corp | Métodos e formas de dosagem para libertação controlada de paliperidona |
US20050232995A1 (en) * | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
US20050208132A1 (en) * | 2002-07-29 | 2005-09-22 | Gayatri Sathyan | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
MXPA05000294A (es) | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
AU2003225945B2 (en) * | 2002-09-28 | 2009-04-23 | Mcneil-Ppc, Inc. | Immediate release dosage form comprising shell having openings therein |
US7807197B2 (en) * | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
EP2255795A1 (en) * | 2002-09-28 | 2010-12-01 | McNeil-PPC, Inc. | Immediate release dosage form comprising shell having openings therein |
AU2003284899A1 (en) * | 2002-10-29 | 2004-05-25 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
ATE376419T1 (de) | 2002-12-27 | 2007-11-15 | Otsuka Pharma Co Ltd | Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten |
JP2006528676A (ja) * | 2003-05-16 | 2006-12-21 | ファイザー・プロダクツ・インク | 非定形型抗精神病薬と、gaba調節薬及び/又は抗痙攣薬の治療上の組合せ |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
AU2004264316A1 (en) * | 2003-08-06 | 2005-02-24 | Alza Corporation | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
US7611728B2 (en) * | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
US20050260268A1 (en) * | 2003-09-26 | 2005-11-24 | Modi Nishit B | Methods and dosage forms for controlled delivery of alprazolam |
US8067029B2 (en) | 2004-01-13 | 2011-11-29 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
US7879354B2 (en) | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
US8252331B2 (en) * | 2004-12-03 | 2012-08-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Osmotic device containing amantadine and an osmotic salt |
US8574626B2 (en) | 2004-12-03 | 2013-11-05 | Osmotica Kereskedelmi és Szolgáltató KFT | Osmotic device containing amantadine and an osmotic salt |
AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
WO2006085168A2 (en) * | 2005-01-07 | 2006-08-17 | Ranbaxy Laboratories Limited | Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide |
EP1690540A1 (en) * | 2005-02-15 | 2006-08-16 | Neuro3D | Composition comprising ocaperidone |
US8673352B2 (en) * | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US20070212412A1 (en) * | 2005-09-08 | 2007-09-13 | H. Lundbeck A/S | Stable solid formulation of sertindole |
US20070087055A1 (en) * | 2005-10-14 | 2007-04-19 | David Jan | Directly compressible extended release alprazolam formulation |
WO2007073702A2 (es) | 2005-12-29 | 2007-07-05 | Osmotica Corp. | Comprimido multicapa con combinación de triple liberación |
US20070166381A1 (en) * | 2006-01-06 | 2007-07-19 | Iran Reyes | Osmotic dosage form with controlled release and fast release aspects |
US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US5225198A (en) * | 1991-08-27 | 1993-07-06 | Cygnus Therapeutic Systems | Transdermal administration of short or intermediate half-life benzodiazepines |
ATE188375T1 (de) * | 1992-11-17 | 2000-01-15 | Yoshitomi Pharmaceutical | Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung |
TW235239B (es) * | 1992-11-20 | 1994-12-01 | Pfizer | |
AU7706598A (en) * | 1997-05-30 | 1998-12-30 | Laboratorios Phoenix U.S.A., Inc. | Multi-layered osmotic device |
-
2001
- 2001-01-08 US US09/756,497 patent/US6599532B2/en not_active Expired - Fee Related
- 2001-01-09 CA CA002396214A patent/CA2396214A1/en not_active Abandoned
- 2001-01-09 AU AU2001227758A patent/AU2001227758A1/en not_active Abandoned
- 2001-01-09 WO PCT/US2001/000637 patent/WO2001051040A1/en active Application Filing
- 2001-01-11 AR ARP010100117A patent/AR026832A1/es unknown
- 2001-01-12 UY UY26534A patent/UY26534A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20020051807A1 (en) | 2002-05-02 |
CA2396214A1 (en) | 2001-07-19 |
AU2001227758A1 (en) | 2001-07-24 |
WO2001051040B1 (en) | 2002-03-07 |
UY26534A1 (es) | 2001-09-28 |
WO2001051040A1 (en) | 2001-07-19 |
US6599532B2 (en) | 2003-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR026832A1 (es) | Dispositivo que contiene alprazolam y un agente antipsicotico. | |
AR026819A1 (es) | Dispositivo osmotico que contiene venlafaxina y un agente antipsicotico | |
AR026818A1 (es) | Dispositivo osmotico que contien pseudoefedrina y un antagonista h1 | |
GT200400085A (es) | Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de laresistenciaal calor y a la humedad. | |
ES2173708T3 (es) | Composicion filmogena que comprende un poliuretano en dispersion acuosa y un agente plastificante. | |
DOU2000000116U (es) | Paño limpiador que contiene un agente antimicrobiano que se libera de manera controlada | |
CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
ATE297735T1 (de) | Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff | |
ATE369125T1 (de) | Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe | |
ES2189410T3 (es) | Formulacion farmaceutica en aerosol. | |
AR037948A1 (es) | Un articulo absorbente con estructura absorbente estabilizada que tiene una rigidez de compresion lateral no uniforme | |
NO20033100L (no) | Uorganiske matrikssammensetninger og kompositter som inneholder matrikssammensetningen | |
AR048194A1 (es) | Metodo mejorado de blanqueamiento dental | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
CU23262A3 (es) | Jeringa de seguridad con aguja retraible de intercambio | |
CO5680108A1 (es) | Compuestos para el tratamiento de la disfuncion sexual femenina | |
HN2001000006A (es) | Antagonistas del factor liberador de corticotropina | |
NO20024528L (no) | Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen | |
MXPA02010502A (es) | Un dispositivo intravaginal que contiene progesterona, util como inductor del celo en bovinos productores de carne y leche y el procedimiento para prepararlo. | |
AR012671A1 (es) | Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos | |
HN2002000299A (es) | Derivados del 3- azabiciclo[3.1.0] hexano | |
UY26889A1 (es) | Compuestos farmacéuticos | |
BR0004335A (pt) | Substituicão aloplástica para osso longo | |
BR9916830A (pt) | Formulações aerossóis farmacêuticas contendo fluoroalcanos e budesonide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |